An observational study in Risk Assessment, Resilience, Psychological and Depression, sponsored by University of Texas Southwestern Medical Center. Active, not recruiting at 1 site in United States. Open to participants aged 10 Years to 24 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by University of Texas Southwestern Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Depression by University of Texas Southwestern Medical Center — 6 open to participants now, 9 under way, none of them phase 3. Depression · University of Texas Southwestern Medical Center.
Among the 47 studies in Depression by University of Texas Southwestern Medical Center, this one is the 4th largest by planned enrollment of the 10 observational ones that give a count, is one of 5 that started in 2016, is one of 10 observational ones, and was the 26th registered.
8,582 studies on the registry are indexed under Depression; 1,723 are open to participants now.
Browse Depression studies →6 of the 47 studies in Depression by University of Texas Southwestern Medical Center are open now, in 1 country. Recruiting first, the newest first:
University of Texas Southwestern Medical Center · Sites in United States
Ages 12–18
University of Texas Southwestern Medical Center · Sites in United States
Ages 18–65
University of Texas Southwestern Medical Center · Sites in United States
Healthy volunteers
University of Texas Southwestern Medical Center · Sites in United States
Ages 8–20
University of Texas Southwestern Medical Center · Sites in United States
Ages 18–50
By country, each count listing its studies:
Of the 1,089 Depression studies recruiting now, 470 (43%) set no upper age limit and 519 (48%) stop at 75 or younger; 203 take children under 18; 311 take healthy volunteers.
This study: 10 Years to 24 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 5 · Phase 4 7
First in 2000; this study’s year is marked. 5 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,500 is above the median of 175 across 1,259 observational studies indexed under Depression.
Median enrollment 40 across the 37 interventional studies, 744 across the 10 observational. Of the 36 that completed or were terminated, 17 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Texas Southwestern Medical Center is the lead sponsor of 1,012 studies on the registry; 201 are open to participants now.
Of its 139 completed or terminated interventional studies of FDA-regulated products, 105 (76%) have results posted.
3 of the studies in Depression by University of Texas Southwestern Medical Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03906435University of Texas Southwestern Medical CenterPreventing Vulnerable Child Syndrome in the NICU With Cognitive Behavioral Therapy (PreVNT Trial) | 2026-12-01 |
| NCT07430774University of Texas Southwestern Medical CenterParent-Adolescent Relationships, Emotional Regulation, and HRV in Adolescents With Depression | 2027-04-01 |
| NCT06424184University of Texas Southwestern Medical CenterAccelerated rTMS for Substance Use Disorder and Depression | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 47 studies in Depression by University of Texas Southwestern Medical Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
RAD is a 10-year natural history, longitudinal, prospective assessment study of a cohort of 2,500 participants (ages 10-24 years) that will help uncover the socio-demographic, lifestyle, clinical, psychological, and neurobiological factors that contribute to resilience among children, adolescents, and young adults at-risk for mood and anxiety disorders. As this is an exploratory study, we will assess a comprehensive panel of carefully selected participant specific parameters, including socio-demographic, life habits, clinical, biological, behavioral, neurophysiological, and neuroimaging. The study is designed to observe and collect factors associated with resilience in a non-invasive fashion; no interventions or treatments will be conducted during the project. Assessments will be conducted up to 4 times per year for up to 10 years, as well as a baseline visit. Study visits will be conducted in person whenever feasible but may be completed by phone/mail/computer, if an in-person visit is not possible.
The primary objective of this initiative is identify and validate biosignatures of resilience. Specifically, the research will identify protective factors (socio-demographic, lifestyle, clinical and behavioral assessments, fluid-based biomarkers, genomics, neuroimaging, EEG, and cell-based assays) that reduce risk of developing mood and anxiety disorders in adolescents and young adults at risk for these illnesses.
Presence and severity of symptoms will be assessed over 10 years using questionnaires for symptom changes, social factors, and overall quality of life. Other outcomes generated from this study will include rate of change in quantitative measures of brain function, of depression relevant brain regions correlated with systems-levels behavior and other functional neuro-circuitry MRI measures. Rate of change of specified biochemical biomarkers will also be assessed. Integration of these measures will provide an unmatched understanding into the mechanisms of resilience and protection against depression and anxiety disorders and holds tremendous promise for identifying targets for prevention strategies.
Specific Aims of the RAD Study:
Aim 1 - Examine baseline biosignatures and independent factors (demographic, social, environmental, genetic, EEG, and fMRI) associated with resilience in at-risk adolescents and young adults.
Aim 2 - Examine changes in the biomarker factors annually for 10 years to determine for plasticity of these biomarkers.
Aim 3 - Examine the interaction between psychiatric symptoms and changes in the biopsychosocial signature.
Aim 4 - Evaluate psychological, social, and physiological correlates, from mobile based data, of mood changes to construct a model of risk and resilience to depression and mood disorders among adolescents and young adults.
Participants will be males or females between ages 10 and 24 who have provided informed consent.
Inclusion Criteria:
Belong to one of the following groups:
Exclusion Criteria:
Exclusion for Healthy Controls
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Youth aged 10-24, male and female of all races and ethnicity with either: a) a personal history (anxiety disorder, conduct disorder, substance use disorder, etc.) of a mental health disorder that is a not a mood disorder, OR b) no current or past mood disorder, but with Biological Family history (ex. mother, father, siblings, uncles, aunts, etc.) of mood disorder, substance use disorder, suicide deaths or attempts, or other mental health disorder.
Youth aged 10-24, male and female of all races and ethnicity with no psychiatric diagnoses (no history of mood disorders and having no relative with a history of a mood disorder).
Depression Severity
Longitudinal changes in depression presence and severity of participants without a mood disorder on Patient Health Questionnaire (PHQ-9). Interpretation of Total Scores: 0-4: Minimal depression or no depression 5-9: Mild depression 10-14: Moderate depression 15-19: Moderately severe depression 20-27: Severe depression
Time frame: 10 Years
Functioning (MRI)
Comparison of Longitudinal changes in functioning as measured by Magnetic Resonance Imaging (MRI) in participants without a mood disorder.
Time frame: 10 Years
Functioning (EEG)
Comparison of Longitudinal changes in functioning as measured by quantitative electroencephalography (EEG) in participants without a mood disorder.
Time frame: 10 Years
Biomarkers (Proteomic Methods)
Comparison of longitudinal changes in fluid-based biomarkers as measured by proteomic methods in participants without a mood disorder.
Time frame: 10 Years
Biomarkers (Metabolomics Methods)
Comparison of longitudinal changes in fluid-based biomarkers as measured by metabolomics methods in participants without a mood disorder.
Time frame: 10 Years
Biomarkers (Transcriptomic Methods)
Comparison of longitudinal changes in fluid-based biomarkers as measured by transcriptomic methods in participants without a mood disorder.
Time frame: 10 Years
Biomarkers (Genomic Methods)
Comparison of longitudinal changes in fluid-based biomarkers as measured by genomic methods in participants without a mood disorder.
Time frame: 10 Years
Biomarkers (Epigenomic Methods)
Comparison of longitudinal changes in fluid-based biomarkers as measured by epigenomic methods in participants without a mood disorder.
Time frame: 10 Years
Plan to share: Undecided
No publications or documents are linked to this record.
Started Aug 2016 (actual). Primary completion is estimated for Dec 2031, 184 months after the start.
Of 460 non-industry observational studies under Depression, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 63. This study's planned 184 months is above that.
Counting every sponsor, half of 493 studies reached it within 32 months; a quarter within 13 and three quarters within 62.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Texas Southwestern Medical Center →